THE WIRE · № 59945
Fabry Disease Market Outlook: 6 Upcoming Therapies Set to Influence the Future Market Landscape
01 THE MACHINE READ
WHY IT MATTERS.
Pipeline of Fabry disease therapies signals competitive shifts among rare-disease drugmakers, but no pricing or approval data is given.
Early-stage Fabry therapies, no near-term revenue impact
Trial readouts or approvals for listed candidates
No efficacy or timeline data provided
FULL DISPATCH
The emerging Fabry disease market landscape holds a diverse range of therapeutic alternatives for treatment, including Venglustat (Sanofi Genzyme), Lucerastat (Idorsia Pharmaceuticals), Isaralgagene civaparvovec (ST-920; Sangamo Therapeutics), AMT-191 (UniQure), AL1211 (AceLink...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
Blue Shield of California Expands Medicare Offerings for 2027 with New Plans, Enhanced Benefits, and Digital Tools2026-10-01 15:02 UTC
New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 20262026-10-01 11:30 UTC
Codoxo Awarded on TIME's List of the World's Top HealthTech Companies 20262026-10-01 12:01 UTC
M&A slows in Q3 but Vertex snags one of the year’s biggest in $10B Crinetics buy2026-10-01 12:45 UTC
Cancer treatment is brutal on the skin. So why isn't skincare part of the treatment?2026-10-01 13:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.